Normal view

Received — 13 April 2026 ⏭

(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
Effect of the Maxing Huoqiao granule on nonsevere community-acquired pneumonia: A multicenter, double-blind, placebo-controlled randomized trial Qingming Ke · Caiping Zhao · Shengda Luo · Yuntao Liu · Ye Ye · Xingdong Lin · Jing Zeng · Xinghua Liu · Yang Liao · Hongtao Li · Shu Chen · Hong Ren · Liang Liu · Hudan Pan
Pharmacol Res. 2026 Apr 9:108186. doi: 10.1016/j.phrs.2026.108186. Online ahead of print.ABSTRACTCommunity-acquired pneumonia (CAP) remains a major global public health challenge with substantial morbidity and mortality. Although preclinical studies suggest that Maxing Huoqiao (MXHQ) granule may have therapeutic potential for pneumonia, high-quality clinical evidence is still limited. We conducted a multicenter, double-blind, randomized, placebo-controlled trial at two tertiary hospitals in Chin
12 April 2026 at 18:00

Effect of the Maxing Huoqiao granule on nonsevere community-acquired pneumonia: A multicenter, double-blind, placebo-controlled randomized trial

(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)

By: Qingming Ke · Caiping Zhao · Shengda Luo · Yuntao Liu · Ye Ye · Xingdong Lin · Jing Zeng · Xinghua Liu · Yang Liao · Hongtao Li · Shu Chen · Hong Ren · Liang Liu · Hudan Pan

12 April 2026 at 18:00

Pharmacol Res. 2026 Apr 9:108186. doi: 10.1016/j.phrs.2026.108186. Online ahead of print.

ABSTRACT

Community-acquired pneumonia (CAP) remains a major global public health challenge with substantial morbidity and mortality. Although preclinical studies suggest that Maxing Huoqiao (MXHQ) granule may have therapeutic potential for pneumonia, high-quality clinical evidence is still limited. We conducted a multicenter, double-blind, randomized, placebo-controlled trial at two tertiary hospitals in China to evaluate the clinical efficacy of MXHQ as adjunctive therapy and to explore its potential mechanisms in adults with nonsevere CAP receiving standard moxifloxacin treatment. A total of 96 patients were enrolled and randomized (1:1:1) to receive standard-dose MXHQ, low-dose MXHQ, or placebo in addition to moxifloxacin for 7 days, with a 14-day follow-up. The primary endpoint was clinical cure, defined as composite recovery of major respiratory symptoms, lung rales, and fever; secondary endpoints included symptom relief, radiographic improvement, and safety. Compared with placebo, standard-dose MXHQ was associated with a higher day-14 clinical cure rate (30.78% vs. 68.97%; RR = 0.45, 95% CI = 0.24-0.83; P < 0.01). Furthermore, the standard-dose intervention was correlated with a shorter time to relief and recovery of cough and sputum (P < 0.05), as well as improvements in symptom scores (P < 0.05) and promoting lesion absorption on chest CT (P < 0.05). Low-dose MXHQ showed no significant clinical benefit, whereas safety profiles were comparable across all groups. Transcriptomic analyses of peripheral blood mononuclear cells, complemented by a Streptococcus pneumonia animal model, indicated that the clinical benefits of MXHQ are linked to the modulation of inflammation and innate immunity. These omics and in vivo observations suggest a potential mechanism underlying the protective effects of MXHQ against inflammatory injury and promotion of tissue repair, involving the regulation of anti-inflammatory mediators and tissue repair-related factors. (Chictr.org.cn, ID Number: ChiCTR2400082095).

PMID:41966499 | DOI:10.1016/j.phrs.2026.108186

Received — 11 March 2026 ⏭

cs.AI, q-bio.NC updates on arXiv.org
Tiny but Mighty: A Software-Hardware Co-Design Approach for Efficient Multimodal Inference on Battery-Powered Small Devices Yilong Li · Shuai Zhang · Yijing Zeng · Hao Zhang · Xinmiao Xiong · Jingyu Liu · Pan Hu · Suman Banerjee
arXiv:2510.05109v5 Announce Type: replace-cross Abstract: Large Multimodal Models (LMMs) are inherently modular, consisting of vision and audio encoders, projectors, and large language models. Yet, they are almost always executed monolithically, which underutilizes the heterogeneous accelerators (NPUs, GPUs, DSPs) in modern SoCs and leads to high end-to-end latency. In this paper, we present NANOMIND, a hardware--software co-design inference framework for Large Multimodal Models (LMMs) that bre
10 March 2026 at 12:00

Tiny but Mighty: A Software-Hardware Co-Design Approach for Efficient Multimodal Inference on Battery-Powered Small Devices

cs.AI, q-bio.NC updates on arXiv.org

By: Yilong Li · Shuai Zhang · Yijing Zeng · Hao Zhang · Xinmiao Xiong · Jingyu Liu · Pan Hu · Suman Banerjee

10 March 2026 at 12:00

arXiv:2510.05109v5 Announce Type: replace-cross Abstract: Large Multimodal Models (LMMs) are inherently modular, consisting of vision and audio encoders, projectors, and large language models. Yet, they are almost always executed monolithically, which underutilizes the heterogeneous accelerators (NPUs, GPUs, DSPs) in modern SoCs and leads to high end-to-end latency. In this paper, we present NANOMIND, a hardware--software co-design inference framework for Large Multimodal Models (LMMs) that breaks large models into modular ``bricks'' (vision, language, audio, etc.) and maps each to its ideal accelerator. The key insight is that large models can be broken into modular components and scheduled to run on the most appropriate compute units. It performs module-level dynamic offloading across accelerators on unified-memory SoCs. By combining customized hardware design, system-level scheduling, and optimized low-bit computation kernels, we demonstrate our framework with a compact, battery-powered device capable of running LMMs entirely on device. This prototype functions as a self-contained intelligent assistant that requires no network connectivity, while achieving higher throughput and superior power efficiency under strict resource constraints. The design further bypasses CPU bottlenecks and reduces redundant memory usage through token-aware buffer management and module-level coordination. Our system outperforms existing implementations in resource efficiency, cutting energy consumption by 42.3\% and GPU memory usage by 11.2\%. This enables a battery-powered device to run LLaVA-OneVision with a camera for nearly 20.8 hours.